Evaluating immune markers in respiratory viral infections
Evaluation of the Type 1 IFN Response in Viral Infections
This study is testing if certain immune markers in the body can help doctors diagnose respiratory viral infections more easily and accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Lyon, Rhone) |
| Trial ID | NCT06017310 on ClinicalTrials.gov |
What this trial studies
The Respiferon Project aims to improve the diagnosis of respiratory viral infections by evaluating the performance of immune markers, specifically interferon I and III, derived from host responses. This observational study will analyze nasopharyngeal samples that have tested positive for viruses, utilizing established viral culture techniques to confirm their replicative nature. By focusing on the immune response rather than directly identifying pathogens, the study seeks to streamline the diagnostic process and address the challenges posed by the variety of respiratory viruses.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with positive nasopharyngeal samples for respiratory viruses that have been confirmed through viral culture.
Not a fit: Patients without positive nasopharyngeal samples or those who do not consent to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to faster and more accurate diagnostic tests for respiratory viral infections, improving patient outcomes.
How similar studies have performed: While the approach of using immune markers for diagnosis is promising, it is still relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Positive nasopharyngeal samples for the detection of a virus, for which the replicative character has been established by the viral culture technique (500µL minimum required) * Samples kept at the CRB since 2018 * Information to patients carried out and non-objection collected- Exclusion Criteria: * N/A
Where this trial is running
Lyon, Rhone
- Infective Agents Institute, Croix rousse Hospital — Lyon, Rhone, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.